Synlett 2010(12): 1837-1840  
DOI: 10.1055/s-0030-1258115
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Reaction of 1-Amino Bisphosphinic Acids with Acid Chlorides: Synthesis of Novel Cyclic 1-Hydroxy-1′-amino-1,1-bisphosphinic Acids

Babak Kaboudin*a, Fariba Saadatia, Tsutomu Yokomatsub
a Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Gava Zang, Zanjan 45137-66731, Iran
Fax: +98(241)4249023; e-Mail: kaboudin@iasbs.ac.ir;
b School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horonouchi, Hachioji, Tokyo 192-0392, Japan
Further Information

Publication History

Received 23 April 2010
Publication Date:
30 June 2010 (online)

Abstract

Treatment of 1-amino bisphosphinic acids with HMDS followed by reaction with acid chlorides gives 1-hydroxy-1′-amino-1,1-bisphosphinic acid in good yields. The reaction gave a mixture of the racemate and meso form of 1-hydroxy-1′-amino-1,1-bisphos­phinic acid. The stereochemistry of the readily separable diastereo­mer was confirmed after converting to the corresponding novel cyclic 1-hydroxy-1′-amino-1,1-bisphosphinic acid.

    References and Notes

  • 1a Ghosh SG. Chan JMW. Lea CR. Meints GA. Lewis JC. Tovian ZS. Flessner RM. Loftus TC. Bruchhaus I. Kendrick H. Croft SL. Kemp RG. Kobayashi S. Nozaki T. Oldfield E. J. Med. Chem.  2004,  47:  175 
  • 1b Martin BM. Grimley JS. Lewis JC. Heath LH. Bailey BN. Kendrick H. Yardley V. Caldera A. Lira R. Urbina JA. Moreno SNJ. Docampo R. Croft SL. Oldfield E. J. Med. Chem.  2001,  44:  909 
  • 1c Takeuchi M. Sakamoto S. Yoshida M. Abe T. Isomura Y. Chem. Pharm. Bull.  1993,  41:  688 
  • 1d Gittens SA. Bansal G. Zernicke RF. Uludag H. Adv. Drug Deliv. Rev.  2005,  57:  1011 
  • 1e Kavanagh KL. Guo K. Dunford JE. Wu X. Knapp S. Ebetino FH. Rogers MJ. Russel RGG. Opermann U. Proc. Natl. Acad. Sci. U.S.A.  2006,  103:  7829 
  • 1f Sanders JM. Gómez AO. Mao J. Meints GA. Van Brussel EM. Burzynska A. Kafarski P. Gonzáles-Pacanowska D. Oldfield E. J. Med. Chem.  2003,  46:  5171 
  • 2 Collinsova M. Jiracek J. Curr. Med. Chem.  2000,  7:  629 ; and references cited therein
  • 3 Widler L. Jaeggi KA. Glatt M. Muller K. Bachmann R. Bisping M. Born AR. Cortesti R. Guiglia G. Jeker H. Klein R. Ramseier U. Schmid J. Schreiber G. Seltenmeyer Y. Green JR. J. Med. Chem.  2002,  89:  3721 
  • 4 Fleisch H. Breast Cancer Res.  2002,  4:  30 
  • 5 Kotsikorou E. Song Y. Chan JMW. Faelens S. Tovian Z. Broderick E. Bakarala N. Docampo R. Oldfield E. J. Med. Chem.  2005,  48:  6128 
  • 6 Du Y. Jung KY. Wiemer DF. Tetrahedron Lett.  2002,  43:  8665 
  • 7 Abdou WM. Shaddy AA. ARKIVOC  2009,  (ix):  143 
  • 8 Luckman SP. Coxon FP. Ebetino FH. Russell GG. Rogers MJ. J. Bone Miner. Res.  1998,  13:  1668 
  • 9 Kleiner H.-J, and Regnat D. inventors; US  5,624,979. 
  • 10 Stowasser B. Budt K.-H. Jian-Qi L. Peyman A. Ruppert D. Tetrahedron Lett.  1992,  33:  6625 
  • 11a Dreyer GB. Abdel-Meguid SS. Zhao B. Murthy K. Winborne E. Choi JW. DesJarlais RL. Minnich MD. Culp JS. Debouck C. Tomaszek TA. Meek TD. Biochemistry  1993,  32:  7972 
  • 11b Cristau H.-J. Herve A. Virieux D. Tetrahedron  2004,  60:  877 
  • 11c Kaboudin B. Haruki T. Yamaghishi T. Yokomatsu T. Tetrahedron  2007,  63:  8199 
  • 11d Kaboudin B. Haruki T. Yamagishi T. Yokomatsu T. Synthesis  2007,  3226 
  • 12 Kaboudin B. Saadati F. Tetrahedron Lett.  2009,  50:  1450 
  • 13 Matziari M. Georgiadis D. Dive V. Yiotakis A. Org. Lett.  2001,  3:  659 
14

The aldehyde (3 mmol) was added to ammonium hydroxide (30%, 15 mL), and the solution was stirred for 5 h at reflux. During this time, a white precipitate formed. The precipitate was removed by filtration and dried. The solid was dissolved in 5 mL of EtOH, H3PO2 (5 mmol, anhyd) was added to this mixture, and the resulting solution was stirred for 2-12 h at reflux. The solvent was evaporated and the mixture resolved in acetone by heating. Dropwise addition of H2O gave the crude product as a white solid. The crude product was washed with EtOH and dried in air at r.t. to give product 2 in 40-71% yield.¹² The solid product was washed with EtOH-H2O (50 mL, 9:1) and dried in air at r.t. to give a single diastereomer. A mixture of phosphinic acid 2 (one diastereomer, 1 mmol) and 1,1,1,3,3,3-hexamethyl-disilazane (5 mmol, 1 mL) was heated at 110 ˚C for 2 h under Ar. The mixture was then cooled to r.t. Acid chloride (1 mmol) was added dropwise, and the resulting mixture was stirred at r.t. for 12 h. The mixture was cooled in an ice bath, absolute EtOH (10 mL) was added, and the reaction mixture was stirred for 2 h at r.t. The removal of the solvent gave a residue, out of which a white solid precipitated after adding absolute EtOH (10 mL). The solid was washed with EtOAC (50 mL) and EtOH (50 mL), and gave pure novel cyclic amino bisphosphinic acid dl-5 as a white solid. All products gave satisfactory spectroscopic data in accordance with the assigned structures.
Analytical and Spectral Data for Compounds dl -5
Compound 5a: mp 234-236 ˚C. ¹H NMR (250 MHz, D2O): δ = 2.21 (6 H, s), 5.02 (1 H, d, J = 10.3 Hz), 5.27 (1 H, d, J = 10.5 Hz), 7.10-7.85 (13 H, m). ³¹P NMR (101.2 MHz, D2O-NaOD-H3PO4): δ = 21.58 (d, J pp = 9.1 Hz), 22.29 (d, J pp = 9.1 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 20.1, 56.2 (d, J PC = 89.3 Hz), 59.3 (d, J PC = 86.7 Hz), 78.5 (dd, J PC = 87.4, 71.4 Hz), 126.5-130.2 (m, Ar), 132.6, 133.7, 135.7, 137.5, 132.7. HRMS: m/z calcd for C23H25NO5P2 [MH+]: 458.1286; found: 458.1291.
Compound 5b: mp 238-240 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.61 (1 H, d, J = 11.5 Hz), 4.73 (1 H, d, J = 11.5 Hz), 7.10-7.38 (13 H, m), 7.64 (2 H, d, J = 7.5 Hz). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 21.03 (d, J pp = 9.1 Hz), 22.08 (d, J pp = 9.1 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.8 (d, J PC = 87.2 Hz), 59.2 (d, J PC = 86.2 Hz), 78.5 (dd, J PC = 86.4, 69.3 Hz,), 126.5-127.8 (m, Ar), 128.3, 135.9, 136.5, 137.8. HRMS: m/z calcd for C21H21NO5P2 [MH+]: 430.0973; found: 430.0966.
Compound 5c: mp 220-222 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.75 (1 H, d, J = 15.0 Hz), 5.02 (1 H, d, J = 8.5 Hz), 7.05-7.40 (13 H, m), 8.20-8.32 (1 H, br). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 19.60 (d, J pp = 10.1 Hz), 22.93 (d, J pp = 10.1 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.9 (d, J PC = 90.6 Hz), 58.8 (dd, J PC = 87.4, 5.0 Hz), 80.0 (dd, J PC = 87.4, 64.2 Hz), 126.0, 127.2, 127.5, 127.9 (d, J PC = 5.0 Hz), 128.3, 128.4, 128.5, 130.5, 132.0, 133.1, 134.2 (d, J PC = 3.8 Hz), 136.2 (d, J PC = 3.8 Hz), 137.5. HRMS: m/z calcd for C21H20ClNO5P2 [MH+]: 464.0584; found: 464.0587.
Compound 5d: mp 241-243 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.74 (1 H, d, J = 14.0 Hz), 4.91 (1 H, d, J = 10.8 Hz), 7.12-7.80 (14 H, m). ³¹P NMR (101.2 MHz, D2O-H3PO4):
δ = 18.78 (d, J pp = 8.5 Hz), 19.98 (d, J pp = 8.5 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.7 (d, J PC = 88.1 Hz), 59.3 (dd, J PC = 90.6, 4.0 Hz), 78.2 (dd, J PC = 87.2, 65.1 Hz), 125.3, 126.7, 126.8, 127.5, 127.7, 128.4, 128.5, 128.6, 128.9, 132.8, 135.2, 136.3, 138.0. HRMS: m/z calcd for C21H20ClNO5P2 [MH+]: 464.0584; found: 464.0593.
Compound 5e: mp 239-241 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.84 (1 H, d, J = 8.0 Hz), 5.18-5.32 (1 H, br), 6.80-7.60 (13 H, m), 7.70-7.90 (1 H, br). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 17.27, 18.05. ¹³C NMR (62.9 MHz, D2O): δ = 56.7 (d, J PC = 86.7 Hz), 58.1 (d, J PC = 93.7 Hz), 78.3 (dd, J PC = 84.9, 74.7 Hz), 115.8, 116.2, 123.9, 128.2 (d, J PC = 7.5 Hz), 128.5-130.5 (m, Ar), 134.2, 134.9, 160.2 (d, J FC = 245.4 Hz). HRMS: m/z calcd for C21H20FNO5P2 [MH+]: 448.0879; found: 448.0883.
Compound 5f: mp 254-256 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.67 (1 H, d, J = 14.7 Hz), 4.79 (1 H, d, J = 11.2 Hz), 7.00 (2 H, t, J = 8.7 Hz), 7.10-7.35 (8 H, m), 7.41 (2 H, d, J = 7.0 Hz), 7.65-7.80 (2 H, br). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 20.82 (d, J pp = 9.5 Hz), 21.84 (d, J pp = 9.9 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.7 (d, J PC = 88.1 Hz), 59.5 (d, J PC = 85.5 Hz), 78.1 (dd, J PC = 87.4, 71.7 Hz), 114.3 (d, J FC = 25.2 Hz), 127.4, 127.7, 128.0-129.0 (m, Ar), 131.3, 135.3, 136.4, 161.8 (d, J FC = 240.3 Hz). HRMS: m/z calcd for C21H20FNO5P2 [MH+]: 448.0879; found: 448.0868. Compound 5g: mp 254-256 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.00-5.00 (2 H, br), 6.50-7.85 (17 H, m). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 19.70. ¹³C NMR (62.9 MHz, D2O): δ = 56.1 (d, J PC = 84.9 Hz), 59.5 (d, J PC = 86.2 Hz), 79.6 (dd, J PC = 84.3, 78.0 Hz), 124.3, 126.5, 127.5, 127.7, 128.0-129.7 (m, Ar), 135.3, 136.0, 137.0. HRMS: m/z calcd for C23H23NO5P2 [MH+]: 456.1130; found: 456.1125. Compound 5h: mp 241-243 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.20-4.80 (2 H, br), 6.90-7.50 (11 H, m), 7.55-7.80 (2H, br). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 20.56 (d, J pp = 8.8 Hz), 21.42 (d, J pp = 8.9 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.2 (d, J PC = 86.8 Hz), 58.7 (d, J PC = 89.3 Hz), 78.5 (dd, J PC = 83.0, 70.5 Hz), 126.8, 126.9, 128.2, 129.0 (d, J PC = 3.8 Hz), 129.5, 129.8 (d, J PC = 3.8 Hz), 132.1, 132.5, 134.7, 135.1, 135.7, 136.4. HRMS: m/z calcd for C21H19Cl2NO5P2 [MH+]: 498.0194; found: 498.0204.
Compound 5i: mp 231-232 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.60-4.80 (1 H, br), 4.90-5.10 (1 H, br), 7.10-7.50 (11 H, m), 7.55-7.80 (1 H, br). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 19.80 (d, J pp = 5.8 Hz), 22.93 (d, J pp = 5.8 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.2 (d, J PC = 91.2 Hz), 58.17 (d, J PC = 91.8 Hz), 79.9 (dd, J PC = 88.7, 66.0 Hz), 126.1, 128.3, 128.5, 129.5 (d, J PC = 3.8 Hz), 129.9 (d, J PC = 3.8 Hz), 130.4, 131.9, 132.5, 132.8, 133.1, 133.2, 134.0 (d, J PC = 3.8 Hz), 134.5 (d, J PC = 3.8 Hz), 135.9. HRMS: m/z calcd for C21H18Cl3NO5P2 [MH+]: 531.9804; found: 531.9803.
Compound 5j: mp 246-248 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.60-4.80 (1 H, br), 4.93 (1 H, d, J = 8.2 Hz), 6.90-7.50 (11 H, m), 7.75-7.95 (1 H, br). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 20.26 (d, J pp = 19.9 Hz), 21.16 (d, J pp = 19.8 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.2 (d, J PC = 87.4 Hz), 57.8 (d, J PC = 92.5 Hz), 75.5-79.5 (m), 116.1 (d, J FC = 25.2 Hz), 123.7, 124.3, 128.4, 129.0, 129.8, 130.0, 132.5, 132.7, 135.0, 135.9, 160.5 (d, J FC = 242.2 Hz). HRMS: m/z calcd for C21H18Cl2FNO5P2 [MH+]: 516.0100; found: 516.0097.
Compound 5k: mp 245-247 ˚C. ¹H NMR (250 MHz, D2O): δ = 5.07 (1 H, d, J = 10.0 Hz), 5.34 (1 H, d, J = 10.5 Hz), 6.90-7.35 (10 H, m), 7.42 (1 H, t, J = 7.8 Hz), 7.58 (1 H, t, J = 7.8 Hz), 7.70 (1 H, d, J = 7.2 Hz). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 12.10, 13.50. ¹³C NMR (62.9 MHz, D2O): δ = 55.4 (d, J PC = 89.5 Hz), 59.4 (d, J PC = 85.7 Hz), 78.1 (dd, J PC = 87.4, 75.5 Hz), 115.5-117.0 (m, Ar), 126.0-132.0 (m, Ar), 134.2, 163.1 (d, J FC = 246.7 Hz). HRMS: m/z calcd for C21H19F2NO5P2 [MH+]: 466.0785; found: 466.0805.
Compound 5l: mp 242-244 ˚C. ¹H NMR (250 MHz, D2O): δ = 4.69 (1 H, d, J = 7.5 Hz), 5.15 (1 H, d, J = 7.5 Hz), 6.90-7.50 (11 H, m), 7.81 (1 H, t, J = 7.5 Hz). ³¹P NMR (101.2 MHz, D2O-H3PO4): δ = 19.83 (d, J pp = 23.3 Hz), 20.63 (d, J pp = 23.3 Hz). ¹³C NMR (62.9 MHz, D2O): δ = 56.0 (d, J PC = 86.9 Hz), 57.5 (d, J PC = 86.4 Hz), 78.1 (dd, J PC = 83.0, 66.7 Hz), 115.1 (d, J FC = 21.5 Hz), 116.1 (d, J FC = 23.6 Hz), 123.7, 124.3, 124.4, 128.8-130.4 (m, Ar), 132.2, 133.0 160.5 (d, J FC = 244.5 Hz), 161.9 (d, J FC = 243.0 Hz), 162.1 (d, J FC = 243.2 Hz). HRMS: m/z calcd for C21H18F3NO5P2 [MH+]: 484.0691; found: 484.0723.

15

The structure was solved by a direct method using SHELXS-97 (Scheldrik,1997) and refined with a full-matrix least-squares method. Molecular formula = C21H27Cl2NO9P2, MW = 570.28, triclinic, space group = P-1, a = 8.9246 (17) Å, b = 11.069 (2) Å, c = 13.181 (3) Å, V = 1280.1 (4) ų, T = 296 K, Z = 2, D x = 1.479 Mg/m³, (Mo-Kα) = 0.71073 Å, R = 0.0367 over independent reflections(5886). Crystallographic data (excluding structure factors) for the X-ray crystal structure analysis reported in this paper have been deposited with the Cambridge Crystallographic Data Center (CCDC) as supplementary publication No. CCDC 750864, copies of these data can be obtained, free of charge, upon application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (1223)336033 or e-mail: deposit@ccdc.cam.ac.uk].